Article Abstract

SWOG study shows significant long-term overall survival for advanced gastrointestinal stromal tumor patients with imatinib treatment

Authors: Marcel Trautmann, Sebastian Huss, Wolfgang Hartmann, Eva Wardelmann


Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract with an annual incidence rate of 7 to 10 per one million people (1,2).